Oct 24, 2023, Jiudian Pharmaceutical have drug license of Loxoprofen Sodium Oral Solution from NMPA. We are the first company which obtain it.

Loxoprofen sodium oral solution was first introduced in Japan in 2001 and is mainly used for rheumatoid arthritis, osteoarthritis, low back pain, shoulder periarthritis, neck and shoulder syndrome, toothache, as well as for anti-inflammatory and analgesic treatment after surgery, trauma and tooth extraction, as well as for antipyretic and analgesic treatment of acute upper respiratory inflammation (including acute upper respiratory inflammation with acute bronchitis). Up to now, no loxoprofen sodium oral solution has been originally marketed in China.

At present, there are 6 kinds of loxoprofen sodium dosage forms on the market in China, which are granules, dispersible tablets, capsules, tablets, gel paste and oral solution. Until now, Jiudian has tablets, gel paste and oral solution.

It enrich the company's product variety, also will provide more options for patients.